2 results
Approved WMOPending
Primary Objective • To determine whether ITCA 650 is non-inferior either to empagliflozin or to glimepiride in reducing glycosylated hemoglobin A1c (HbA1c) or weight in patients with T2D following 65 weeks of treatment. The non-inferiority margins…
Approved WMORecruiting
The primary objective of the SPIRIT*HF study is to compare Spironolactone to Placebo in reducing the rate…